Seng, Elizabeth
Lampl, Christian
Viktrup, Lars
Lenderking, William R.
Karn, Hayley
Hoyt, Margaret
Kim, Gilwan
Ruff, Dustin
Ossipov, Michael H.
Vincent, Maurice
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 1 May 2024
Accepted: 20 August 2024
First Online: 19 September 2024
Declarations
:
: Elizabeth Seng: research funding from the National Institutes of Health, Veterans Health Administration, Cystic Fibrosis Foundation, and the American Heart Association, as well as fees for consulting from GlaxoSmithKline, Theranica, and Abbvie. Christian Lampl: consulting fees and honoraria for lectures/ presentations from AbbVie/Allergan, Eli Lilly, Lundbeck, Novartis, Pfizer and Teva. Principal investigator in clinical trials as the for Eli Lilly. Past-president of the European Headache Federation and associate editor for The Journal of Headache and Pain. Lars Viktrup, Margaret Hoyt, Gilwan Kim,, and Dustin Ruff are employees of Eli Lilly and Company and may own Lilly stock. Maurice Vincent was an employee of Eli Lilly and Company when the study was performed and may own Lilly stock. William R. Lenderking, Hayley Karn, Michael H. Ossipov are employees of Evidera.
: This study was approved by the IRB Ethical & Independent Review Services (Study # 22143-01) and conformed with International Conference on Harmonization guidelines and was conducted in accordance with the World Medical Association Declaration of Helsinki and applicable local data protection laws. All patients provided informed consent via an electronic informed consent form.